2018-2019 Genoa Neuropsychiatric Pharmacy Courses

Information and Access to the Genoa Neuropsychiatric Pharmacy Courses

Genoa is pleased to offer our pharmacists the opportunity to access neuropsychiatric pharmacy courses in conjunction with the College of Psychiatric and Neurologic Pharmacists (CPNP), a specialty membership association.

The objectives of these offerings are to:

  1. Improve your knowledge of psychiatric, neurologic, and substance use disorders.
  2. Improve your confidence.
  3. Improve your knowledge of disorder treatment.
  4. Expose you to best practices.
  5. Improve recognition of clinical relevance.

The Participant Packet and additional links on this web page provide you with details regarding these ACPE approved educational offerings. If you want to gain initial access to the courses, permission must be granted by Genoa. This can be accomplished by clicking on the Request Access link below.

If at any time you have questions, please contact genoa-u@genoa-qol.com.

Technical access issues should be addressed to info@cpnp.org.

Course Information

Hours Topic
2.0 hours
Anxiety and Anxiety-Related Disorders

# 0284-0000-16-030-H01-P (Knowledge)
Author: Jolene Bostwick, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the, signs and symptoms, diagnostic criteria, and pathophysiology for anxiety and anxiety-related disorders.
  2. Explain the use of common rating scales for research, diagnosis, and management of anxiety and anxiety-related disorders.
  3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of anxiety and anxiety-related disorders.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in anxiety and anxiety-related disorders.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for anxiety and anxiety-related disorders.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of anxiety and anxiety-related disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with anxiety and anxiety-related disorders.
1.5 hours
Bipolar Disorder

# 0284-0000-16-031-H01-P (Knowledge)
Author: Carol Ott, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for bipolar disorder.
  2. Explain the use of common rating scales for research, diagnosis, and management of bipolar disorder.
  3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of bipolar disorder.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in bipolar disorder.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for bipolar disorder.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of bipolar disorder in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with bipolar disorder.
1.5 hours
Depression

# 0284-0000-16-033-H01-P (Knowledge)
Author: Cynthia A. Gutierrez, PharmD, MS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for depression.
  2. Explain the use of common rating scales for research, diagnosis, and management of depression.
  3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of depression.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in depression.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for depression.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of depression in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with depression.
1.0 hour
Neurodevelopmental, Disruptive, Impulse-Control and Conduct Disorders

# 0284-0000-16-038-H01-P (Knowledge)
Author: Sandra Mullen, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for neurodevelopmental, disruptive, impulse-control, conduct and genetic disorders.
  2. Explain the use of common rating scales for research, diagnosis, and management of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
  3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in neurodevelopmental, disruptive, impulse-control, and conduct disorders.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for neurodevelopmental, disruptive, impulse-control, and conduct disorders.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of neurodevelopmental, disruptive, impulse-control, and conduct disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Recognize the behavioral phenotypes, major medical complications, risk factors, pathogenesis, clinical course, and drug therapy treatment options for patients with the following syndromes:
    • Down Syndrome
    • Prader-Willi Syndrome
    • Fragile X Syndrome
    • Klinefelter’s Syndrome
    • Rett’s Syndrome
  10. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with neurodevelopmental, disruptive, impulse-control, and conduct disorders.
2.0 hours
Schizophrenia Spectrum and Other Psychotic Disorders

# 0284-0000-16-040-H01-P (Knowledge)
Author: Lisa W. Goldstone, MS, LPC, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for schizophrenia and movement disorders.
  2. Explain the use of common rating scales for research, diagnosis, and management of schizophrenia and movement disorders.
  3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of schizophrenia and movement disorders.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in schizophrenia and movement disorders.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for schizophrenia and movement disorders.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of schizophrenia and movement disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with schizophrenia and movement disorders.
1.5 hours
Sleep-Wake Disorders

# 0284-0000-16-041-H01-P (Knowledge)
Author: Megan Maroney, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for sleep-wake disorders.
  2. Explain the use of common rating scales for research, diagnosis, and management of sleep-wake disorders.
  3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of sleep-wake disorders.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in sleep-wake disorders.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for sleep-wake disorders.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of sleep-wake disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with sleep-wake disorders.
1.5 hours
Substance-Related Disorders

# 0284-0000-16-042-H01-P (Knowledge)
Author: Calleen Lavinghousez, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for substance use disorders.
  2. Explain the use of common rating scales for research, diagnosis, and management of substance use disorders.
  3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of substance use disorders.
  4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in substance use disorders.
  5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for substance use disorders.
  6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
  7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
  8. Describe the management of substance use disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
  9. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with substance use disorders.
1 hour
Stop the Benzodiazepines: Identifying High Risk Patient Populations and Successfully Tapering these Medications

# 0284-0000-17-009-H01-P (Application)
Author: Kristina Ward, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Explain the risks associated with chronic benzodiazepine use.
  2. Select patients at increased risk of adverse outcomes secondary to benzodiazepines.
  3. Compare evidence-based non-pharmacologic and pharmacologic strategies for benzodiazepine discontinuation.
  4. Design a benzodiazepine withdrawal protocol based on patient-specific characteristics that minimizes withdrawal symptoms.
1 hour
Walking the Tight Rope: Recognizing and Responding to Substance Use Disorders During Management of Chronic Pain

# 0284-0000-17-002-H01-P (Application)
Author: Michele Matthews, PharmD, BCACP, CPE, FASHP
Learning Objectives
At the end of this program, the participant should be able to:

  1. Explain the potential roles of the psychiatric pharmacist in Screening, Brief-intervention, and Referral to Treatment (SBIRT).
  2. Create a plan to manage risk of addiction in patients treated with chronic opioid therapy based on universal precautions of prescribing.
  3. Describe the role of medication assisted treatment in the patient with chronic pain and opioid use disorder.
  4. Develop a treatment and monitoring plan for a patient with acute or chronic pain syndromes treated with buprenorphine or methadone.